Drugs

Articles

• taxanes
  5 January 2006

  Definition : Taxanes are a class of diterpenes.
  Taxanes were originally identified from plants of the genus Taxus (yews), and feature a taxadiene core.
  Molecules as paclitaxel (Taxol) and docetaxel (Taxotere) are widely used as chemotherapy agents. cabazitaxel was FDA approved to treat hormone-refractory prostate cancer.
  Taxanes are important drugs in the treatment of ovarian and other cancers, but their efficacy is limited by intrinsic and acquired drug resistance.
  Resistance (...)

• protein kinase inhibitors
  29 August 2005

  protein-kinase inhibitor ; PKIs WKPD
  Definition: A protein kinase inhibitor is a type of enzyme inhibitor that blocks the action of one or more protein kinases. Protein kinases are enzymes that add a phosphate (PO4) group to a protein, and can modulate its function.
  Protein-kinase inhibitors are generally small molecules that show competitive inhibition with respect to ATP.
  Examples
  tyrosine kinase inhibitors (TKIs )
  References
  Bogoyevitch MA. Therapeutic promise of JNK (...)

• HIV integrase inhibitors
  12 June 2005

  References
  Ciuffi A, Bushman FD. Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet. 2006 Jul;22(7):388-95. PMID: #16730094#
  Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005 Mar;4(3):236-48. PMID: #15729361#

• statins
  9 May 2005

  Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for cholesterol biosynthesis, and are beneficial in the primary and secondary prevention of cardiovascular disease. Most of the benefits of statin therapy are owing to the lowering of serum cholesterol levels.
  However, by inhibiting HMG-CoA reductase, statins can also inhibit the synthesis of isoprenoids, which are important lipid attachments for intracellular signaling molecules, such (...)

• minocycline
  15 June 2005

  minocycline-induced anomalies
  Pathology
  drug-induced hepatitis (minocycline-induced hepatitis)
  drug-induced acute hepatitis
  minocycline-induced pneumonitis
  drug-induced immune thrombocytopenic purpura (DITP) (#12848117#)
  autoimmune features
  minocycline-induced lupus
  serum anti-nuclear antibodies
  elevated immunoglobulin G
  perinuclear antineutrophilic cytoplasmic antibody (pANCA )
  lupus-like syndromes
  serum sickness
  infectious mononucleosis-like syndrome
  vasculitis (...)

• acetaminophen
  30 January 2006

  Acetaminophen (Tylenol)

• sunitinib
  2 June 2009

  Definition: Sunitinib (marketed as Sutent, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTKs) inhibitor (multiRTKs inhibitors).
  Sunitinib was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006.
  The concept was of a ATP analogue that would compete with ATP for binding to the catalytic site of receptor tyrosine kinases. This concept led (...)

• NSAIDs
  22 November 2004

  Non-steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory agents (NSAIAs)

• crizotinib
  10 June 2010

  Pfizer drug crizotinibPF-02341066 or 1066, PF-02341066, Xalkori Wikipedia
  Molecular target: ALK
  Definition: Crizotinib is an ALK inhibitor , ROS1 inhibitor and MET inhibitor .
  Crizotinib is undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, advanced non-small cell lung carcinoma (NSCLC ).
  Crizotinib is an oral ALK (anaplastic lymphoma kinase) inhibitor under study in patients with advanced NSCLC carrying the echinoderm (...)

• platinum
  12 June 2005

  The accidental discovery of the anticancer properties of cisplatin and its clinical introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.
  Although carboplatin—a second-generation analogue that is safer but shows a similar spectrum of activity to cisplatin—was introduced in the 1980s, the pace of further improvements slowed for many years.
  However, in the past several years interest in platinum drugs has increased.
  Key developments include the (...)

0 | 10 | 20 | 30